Charts

News

10 Jul, 2024
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced it wil
14 Jun, 2024
These biotech stocks, lacking in profitability but seeding huge potential, should be on your watchlist.
06 Jun, 2024
FARMINGTON HILLS, Mich., June 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that clinical updates on the Company’s lead candidate APX3330 for diabetic retinopathy (DR) will be featured in upcoming presentations at the Clinical Trials at the Summit meeting on June 8 in Park City, Utah, a
22 May, 2024
The Dow Jones index closed higher by 0.2% on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern ...
12 May, 2024
Ocuphire Pharma ( NASDAQ:OCUP ) First Quarter 2024 Results Key Financial Results Revenue: US$1.71m (down 2.2% from 1Q...
10 May, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips OCUP stock results show that Ocuphire Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. The post OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future”
FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. “Ocuphire has made significant progress in 2024, with important developments for both APX3330 and RYZUMVI™,” said Georg
06 May, 2024
FARMINGTON HILLS, Mich., May 06, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data from its ZETA-1 trial evaluating APX3330 in diabetic retinopathy (DR) on a validated binocular person-level scale was presented yesterday at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meet
03 May, 2024
FARMINGTON HILLS, Mich., May 03, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A., M.S., Chief Executive Officer of Ocuphire, will present a company overview at the Aegis Virtual Conference being held May 7-9, 2024. Company management will also be participating in one-on-one meetings throughout t
22 Apr, 2024
FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, M.D. will deliver a paper presentation on oral APX3330 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5-9, 2024 in Seattle, Washington. Key details about Dr. Su’s pres
11 Apr, 2024
Gainers Ontrak (NASDAQ:OTRK) shares increased by 18.7% to $0.45 during Thursday's after-market session. The company's market cap stands ...
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire’s Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the enrollment of the first subject in the LYNX-2 Phase 3 registration study evaluating Phentolamine Ophthalmic Solution
01 Apr, 2024
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS). Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine O
26 Mar, 2024
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or ...
15 Mar, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips OCUP stock results show that Ocuphire Pharma missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. The post OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
13 Mar, 2024
Ocuphire Pharma, Inc. ( NASDAQ:OCUP ) just released its latest yearly report and things are not looking great. It was...
10 Mar, 2024
Ocuphire Pharma ( NASDAQ:OCUP ) Full Year 2023 Results Key Financial Results Revenue: US$19.0m (down 52% from FY 2022...
08 Mar, 2024
FARMINGTON HILLS, Mich., March 08, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “Ocuphire had a successful 2023, with notable achievements on the regulatory and development fronts, pav
26 Feb, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet. To mitigate the downside risks, it may be better to consider undervalued enterprises. Of course, specifically targeting biotech stocks that trade… The post 7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.
23 Feb, 2024
FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that George Magrath, M.D. M.B.A, M.S. CEO of Ocuphire, will be presenting a company overview at the BIO CEO & Investor Conference being held February 26-27 2024 in New York City. Company managem
15 Feb, 2024
FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved equity awards under Ocuphire’s 2021 Inducement Plan, as a material inducement to Ashwath Jayagopal, Ph.D., M.B.A., the Company’s newly appointe
14 Feb, 2024
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointments of Ash Jayagopal, Ph.D., M.B.A.
07 Feb, 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the U.S. economy running at full steam and the labor market continuing to impress onlookers, the concept of value stocks might not be the most popular idea. After all, many of the usual suspects of 2023 are still printing strong returns. However, just for prudence sake, it might be a good idea to consider.... The post 3 Value Stocks to Buy on the Dip: February 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
05 Feb, 2024
FARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that clinical data from its ZETA-1 trial on a person-level scale evaluating APX3330 in diabetic retinopathy (DR) were presented at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference, w
04 Jan, 2024
Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024FARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced it has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the
13 Dec, 2023
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $145.21 per unit.
30 Nov, 2023
Investor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023FARMINGTON HILLS, Mich., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the Company’s CEO, George Magrath M.D., M.B.A., M.S., will deliver a presentation at the Ophthalmology Innovation Summit (OI
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside. The post Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024 appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
27 Nov, 2023
FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved an equity award under Ocuphire’s 2021 Inducement Plan, as a material inducement to Joseph K. Schachle, the Company’s newly appointed Chief Oper
Mr. Schachle Brings Over 30 Years of Experience in Biotech and Pharma with Expertise Across Multiple Functional Areas Including Corporate and Commercial OperationsFARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointment of Joseph (Joe) K. Schachle,
20 Nov, 2023
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that ...
13 Nov, 2023
14:10
FinancialContent
Ocuphire Pharma (NASDAQ:OCUP) reported its Q3 earnings results on Monday, November 13, 2023 at 08:00 AM. Here's what investors need to ...
06 Nov, 2023
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same ...
03 Nov, 2023
11:23
FinancialContent
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P Total US.
01 Nov, 2023
29 Sep, 2023
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $152.54 per unit.
11 Sep, 2023
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same ...
11 Jul, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While investing in penny stocks carries a rough reputation (to put it nicely), these speculative entities just might surprise you. The post Surprise! These 3 Penny Stocks Pack Powerful Financials. appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Wall Street Titan: Here’s My #1 Stock for 2023 The $1 Investment You MUST Take Advantage of Right Now It doesn’t matter if you have $500 or $5 million. Do this now.
15 May, 2023
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure ...
03 May, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While quality matters in the market, these best stocks under $10 to buy gives you some potential diamonds in the rough. The post The 7 Best Stocks Under $10 to Buy in May appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.
27 Apr, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical. The post 7 Small-Cap Biotech Stocks with Massive Potential appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.
21 Apr, 2023
Ocuphire PharmaInc (NASDAQ: OCUP) was plunging over 22% at one point on Friday after the company announced it appointed Rick ...
Gainers Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by 57.0% to $0.41 during Friday's regular session. Adial Pharmaceuticals's ...
Gainers Mangoceuticals, Inc. (NASDAQ: MGRX) shares jumped 207% to $2.84. The company announced Thursday, that it's featured on ...
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping around 50 points on Friday. Following the market ...
05 Apr, 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid the noise of the global markets recently, these speculative biotech stocks to buy might trade with a mind of their own. The post 7 Thrilling Biotech Stocks for Aggressive Investors to Buy appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It
04 Apr, 2023
Gainers Bullfrog AI Hldgs (NASDAQ:BFRG) shares increased by 29.2% to $6.06 during Tuesday's regular session. Trading volume for this ...
13 Feb, 2023
Gainers Clene (NASDAQ:CLNN) stock increased by 51.9% to $2.05 during Monday's pre-market session. The company's market cap stands at ...
27 Jan, 2023
Gainers Vaccitech (NASDAQ:VACC) shares rose 8.5% to $3.2 during Friday's after-market session. The company's market cap stands at ...
26 Jan, 2023
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $2.90. MicroAlgo recently entered into securities purchase agreement ...
Gainers Akanda (NASDAQ:AKAN) shares moved upwards by 157.0% to $0.49 during Thursday's regular session. Trading volume for Akanda's ...
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 100 points on Thursday. Following the market opening ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (IKT) stock is falling on Thursday after the company announced a registered direct offering and private placement. The post Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocuphire Pharma (OCUP) stock is falling on Thursday after the company posted mixed results from a Phase 2 clinical trial. The post Why Is Ocuphire Pharma (OCUP) Stock Down 20% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
Gainers Minerva Surgical (NASDAQ:UTRS) stock moved upwards by 82.4% to $0.69 during Thursday's pre-market session. The company's market ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with an overview of the biggest pre-market stock movers that traders need to watch on Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
25 Jan, 2023
Gainers GT Biopharma (NASDAQ:GTBP) shares increased by 7.4% to $0.91 during Wednesday's after-market session. The market value of their ...
06 Dec, 2022
22 Nov, 2022
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $163.08 per unit.
09 Nov, 2022
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of ...
08 Nov, 2022
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from ...
Ocuphire Pharma Inc(NASDAQ: OCUP) concluded anexclusive license agreementwithFamyGen Life Sciences ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares rose 49.1% to $3.22 during Tuesday's pre-market session. The ...
Gainers Ocuphire Pharma, Inc. (NASDAQ: OCUP) shares rose 27.8% to $2.67 in pre-market trading. Ocuphire Pharma entered into a ...
04 Nov, 2022
26 Oct, 2022
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 47.9% to $0.31 during Wednesday's pre-market session. The ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start off the day with a breakdown of the biggest pre-market stock movers for Wednesday morning and the latest news! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.
14 Sep, 2022
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $178.81 per unit.
12 Aug, 2022
13 May, 2022
24 Mar, 2022

Related Articles